BZU:MILBuzzi Spa Analysis
Data as of 2026-06-11 - not real-time
€44.02
Latest Price
6/10Risk
Risk Level: Medium
Executive Summary
Buzzi S.p.A. (BZU.MI) is trading at €44.02, comfortably below its 20‑day (≈44.37), 50‑day (≈46.01) and 200‑day (≈48.00) simple moving averages, signaling a short‑term bearish bias. The RSI sits at 44, just under the neutral threshold, while the MACD histogram remains negative, reinforcing the down‑trend. Despite the technical weakness, the stock boasts a low trailing P/E of 8.65 and a modest price‑to‑book of 1.12, indicating cheap earnings relative to peers. However, the discounted cash‑flow model places intrinsic value at only about €27.6, well beneath the market price, suggesting the market may be pricing in growth expectations beyond current fundamentals.
Fundamentally, Buzzi delivers solid profitability with a 20.4% profit margin and a healthy operating cash flow of €914 M, supported by a strong cash pile (€1.4 B) that exceeds its total debt (€441 M). The dividend yield of 1.59% is underpinned by a low payout ratio (~13.8%), making the payout sustainable. Analysts remain optimistic, targeting a median price of €54, implying roughly 20% upside, and the consensus recommendation is a “buy”. The company’s diversified presence across Europe, North America, the Middle East and Latin America adds geographic breadth, while volatility remains elevated at ~32% over the past month, albeit with a low beta (~0.47) indicating limited market‑wide correlation.
Fundamentally, Buzzi delivers solid profitability with a 20.4% profit margin and a healthy operating cash flow of €914 M, supported by a strong cash pile (€1.4 B) that exceeds its total debt (€441 M). The dividend yield of 1.59% is underpinned by a low payout ratio (~13.8%), making the payout sustainable. Analysts remain optimistic, targeting a median price of €54, implying roughly 20% upside, and the consensus recommendation is a “buy”. The company’s diversified presence across Europe, North America, the Middle East and Latin America adds geographic breadth, while volatility remains elevated at ~32% over the past month, albeit with a low beta (~0.47) indicating limited market‑wide correlation.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- price below key moving averages and bearish MACD
- decreasing trading volume reducing near‑term liquidity
- proximity to support level around €42.44
Medium Term
1–3 yearsPositive
Model confidence: 8/10
Key Factors
- low P/E and P/B ratios indicating value appeal
- strong cash generation and low debt‑to‑equity profile
- analyst price targets suggesting ~20% upside
Long Term
> 3 yearsPositive
Model confidence: 9/10
Key Factors
- stable dividend with sustainable payout ratio
- diversified geographic footprint mitigating single‑market risk
- consistent profitability margins and solid ROE (~13%)
Key Metrics & Analysis
Financial Health
Revenue Growth2.90%
Profit Margin20.35%
P/E Ratio8.6
ROE13.44%
ROA6.30%
Debt/Equity6.18
P/B Ratio1.1
Op. Cash Flow€914.1M
Free Cash Flow€265.1M
Technical Analysis
TrendBearish
RSI44.0
Support€42.44
Resistance€47.18
MA 20€44.37
MA 50€46.01
MA 200€48.00
MACDBearish
VolumeDecreasing
Fear & Greed Index83.82
Valuation
Fair Value€27.57
Target Price€53.16
Upside/Downside20.76%
GradeFair
TypeBlend
Dividend Yield1.59%
Risk Assessment
Beta0.47
Volatility31.92%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.